

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women**
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit

	Bronx - Lebanon
Participants Enrolled	14
<hr/>	
Period 1 Day 1	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
<hr/>	
Period 1 Day 2	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0
<hr/>	
Period 1 Day 3	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
<hr/>	
Period 1 Day 4	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit**

	Bronx - Lebanon
Period 1 Day 5	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 6	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 7	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 8	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women**
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit

	Bronx - Lebanon
Period 1 Day 9	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 10	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 11	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Day 12	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit**

	Bronx - Lebanon
Period 1 Day 13	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 End Visit	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 1 Washout Visit	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Initiate Period 2	
Expected ²	13
Completed ³	13 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	1

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women**
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit

	Bronx - Lebanon
Period 2 Day 1	
Expected ²	14
Completed ³	11 (79%)
Not Completed	3 (21%)
Missed	3 (21%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 2	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 3	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 4	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit**

	Bronx - Lebanon
Period 2 Day 5	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 6	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 7	
Expected ²	14
Completed ³	11 (79%)
Not Completed	3 (21%)
Missed	3 (21%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 8	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women**
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit

	Bronx - Lebanon
Period 2 Day 9	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 10	
Expected ²	14
Completed ³	11 (79%)
Not Completed	3 (21%)
Missed	3 (21%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 11	
Expected ²	14
Completed ³	13 (93%)
Not Completed	1 (7%)
Missed	1 (7%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 Day 12	
Expected ²	14
Completed ³	12 (86%)
Not Completed	2 (14%)
Missed	2 (14%)
Terminated Early	0 (0%)
Not Expected	0

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.

**MTN 014 - A Phase I Crossover Trial Evaluating the Pharmacokinetics of Tenofovir
Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women
Report Generation Date: April 3, 2015
Visit Cutoff Date: March 27, 2015¹
Retention by Visit**

	Bronx - Lebanon
Period 2 Day 13	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Period 2 End Visit	
Expected ²	14
Completed ³	14 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	0
Safety Phone Call/Termination	
Expected ²	11
Completed ³	11 (100%)
Not Completed	0 (0%)
Missed	0 (0%)
Terminated Early	0 (0%)
Not Expected	3

¹ This report includes data received and entered at SCHARP through this date.

² A visit is considered expected only once the participant's visit window has closed.

³ A visit is considered completed once the Visit Summary form is received and entered at SCHARP.